Holen Sie sich die Stockscreener-App
3.42
2.09%
0.07
Handel nachbörslich:
3.45
0.03
+0.88%
Schlusskurs vom Vortag:
$3.35
Offen:
$3.44
24-Stunden-Volumen:
1.59M
Relative Volume:
0.83
Marktkapitalisierung:
$589.65M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.2214
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
-3.12%
1M Leistung:
-5.00%
6M Leistung:
-13.64%
1J Leistung:
-47.87%
1-Tages-Spanne:
$3.40
$3.61
1-Wochen-Bereich:
$3.025
$3.61
52-Wochen-Spanne:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.42 | 560.34M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Relay Therapeutics (RLAY) Receives Buy Rating from Leerink Partners with $12.00 Price Target - AInvest
Relay Therapeutics Reports Q2 2025 Financial Results and Progress - TipRanks
Will Relay Therapeutics Inc. continue its uptrendReal Time Growth Signal with Smart Setup - Newser
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $19 - 富途牛牛
Why Relay Therapeutics Inc. stock attracts strong analyst attentionGrowth Watchlist for Long Term Positioning - Newser
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst Downgrade - Defense World
RLAY.O Drops 11.7%: Uncovering the Forces Behind the Sudden Move - AInvest
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $4 to $17 - 富途牛牛
Wells Fargo reiterates Equal Weight rating on Relay Therapeutics stock By Investing.com - Investing.com Canada
Relay Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relay Therapeutics reports Q2 EPS (41c), consensus (47c) - TipRanks
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Evaluating Relay Therapeutics' Momentum: Strategic Execution and Pipeline Progress in Q2 2025 - AInvest
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | RLAY Stock News - GuruFocus
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - Stock Titan
Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY) - MSN
Relay Therapeutics Q2 2025 Financial Results and Corporate Highlights Announced for August 7, 2025 - AInvest
What’s the recovery path for long term holders of Relay Therapeutics Inc.Free Capital Preserving Trade Plan Templates - Newser
Relay Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowMomentum Screener with Buy and Sell Areas - Newser
Relay Therapeutics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT - MSN
Relay Therapeutics (RLAY) Expected to Announce Earnings on Thursday - Defense World
What makes Relay Therapeutics Inc. stock price move sharplyUnprecedented profits - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
How does Relay Therapeutics Inc. generate profit in a changing economyOutstanding stock performance - Jammu Links News
Should I hold or sell Relay Therapeutics Inc. stock in 2025Build a winning investment strategy today - Jammu Links News
Is Relay Therapeutics Inc. a good long term investmentDynamic profit opportunities - jammulinksnews.com
What are the latest earnings results for Relay Therapeutics Inc.Unlock exclusive stock market insights - Jammu Links News
Why is Relay Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
Critical Survey: SHINECO (NASDAQ:SISI) vs. Relay Therapeutics (NASDAQ:RLAY) - Defense World
What catalysts could drive Relay Therapeutics Inc. stock higher in 2025Discover stocks with superior performance - Jammu Links News
What drives Relay Therapeutics Inc. stock priceMaximize portfolio growth with professional advice - Jammu Links News
How does Relay Therapeutics Inc. compare to its industry peersGet alerts on high-potential market moves - Jammu Links News
Relay Therapeutics (RLAY): Is H2 2025 the Inflection Point for AI-Driven Drug Discovery? - AInvest
Relay Therapeutics: What's Next For H2 2025? - Seeking Alpha
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 - 富途牛牛
Relay Therapeutics’ Phase 3 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks
Relay Therapeutics president sells $113k in stock - Investing.com India
Relay Therapeutics Inc. stock outlook for YEARLow-Risk Reversal Pattern Analysis Tracker - Newser
Relay Therapeutics president sells $113k in stock By Investing.com - Investing.com Nigeria
Rahmer Peter sells Relay Therapeutics (RLAY) stock worth $62,946 By Investing.com - Investing.com Canada
Relay Therapeutics CFO Catinazzo sells $74,000 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics CFO Catinazzo sells $74,000 in stock - Investing.com
Relay Therapeutics Executives Sell Shares - TradingView
Published on: 2025-07-29 23:02:46 - metal.it
Relay Therapeutics has positive read from Celcuity data, says Barclays - The Globe and Mail
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Jul 28 '25 |
Sale |
3.74 |
1,359 |
5,083 |
393,722 |
| Catinazzo Thomas | Chief Financial Officer |
Jul 29 '25 |
Sale |
3.68 |
18,380 |
67,638 |
335,295 |
| Catinazzo Thomas | Chief Financial Officer |
Jul 28 '25 |
Sale |
3.74 |
1,701 |
6,362 |
353,675 |
| Bergstrom Donald A | President, R&D |
Jul 29 '25 |
Sale |
3.68 |
26,701 |
98,260 |
552,720 |
| Bergstrom Donald A | President, R&D |
Jul 28 '25 |
Sale |
3.74 |
4,069 |
15,218 |
579,421 |
| Adams Brian | Chief Legal Officer |
Jul 29 '25 |
Sale |
3.68 |
18,276 |
67,256 |
371,472 |
| Adams Brian | Chief Legal Officer |
Jul 28 '25 |
Sale |
3.74 |
1,637 |
6,122 |
389,748 |
| Patel Sanjiv | President and CEO |
Jul 09 '25 |
Sale |
3.57 |
61,379 |
219,123 |
765,288 |
| Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
| Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):